Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
KRISHGEN BIOSYSTEMS Immunoassay for the estimation of Faricimab in serum and plasma. Assay Range: 0.5 ng/ml – 10 ng/ml. Validated against ICH M10. Can be used for generics and biosimilars PK studies.
Supplier: KRISHGEN BIOSYSTEMS KBI1326
Pack Size: 1 x 96 wells. Background: Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor. A first in class treatment, Faricimab a humanized antibody that is composed of 2 heavy chains and 2 light chains, used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). It has been approved by the FDA and EMA in 2022. This Faricimab ELISA accurately quantifies faricimab in human samples. If you are looking to use animal samples, please contact us. Krishgen's range of bispecific ELISA for PK studies was Highly Commended in the CiteAb 2023 Innovation Award category. ELISA Features include a pre-coated plate with break-apart wells, standardisation and Lot to Lot Consistency with Precision CV <15%.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?